Holen Sie sich die Stockscreener-App
6.57
3.24%
-0.22
Vorhandelsmarkt:
6.50
-0.07
-1.07%
Schlusskurs vom Vortag:
$6.79
Offen:
$6.84
24-Stunden-Volumen:
527.08K
Relative Volume:
0.42
Marktkapitalisierung:
$479.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.60M
KGV:
-2.3196
EPS:
-2.8324
Netto-Cashflow:
$-67.37M
1W Leistung:
-4.64%
1M Leistung:
-19.09%
6M Leistung:
+40.69%
1J Leistung:
+66.33%
1-Tages-Spanne:
$6.39
$6.93
1-Wochen-Bereich:
$6.39
$7.55
52-Wochen-Spanne:
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
6.57 | 495.58M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Eingeleitet | Guggenheim | Buy |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Quarterly Risk: Is Lexeo Therapeutics Inc forming a bullish divergence2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Volatility Watch: Is Lexeo Therapeutics Inc backed by strong institutional buyingPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Lexeo Therapeutics Announces Head of Research Transition - The Globe and Mail
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - 富途牛牛
Biotech Lexeo to stream Feb investor talks from New York and online - Stock Titan
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program - Yahoo Finance
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program - Finviz
Lexeo TherapeuticsRevolutionizing Heart Health With Gene Therapies - RTTNews
Lexeo Therapeutics Announces Key Executive Leadership Changes - The Globe and Mail
Lexeo Therapeutics Announces Key Leadership Appointments - citybiz
Lexeo Therapeutics appoints new COO and CMO, announces executive transition - Investing.com Nigeria
Lexeo Therapeutics appoints new COO and CMO, announces executive transition By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Executive Appointments - marketscreener.com
Lexeo Therapeutics Announces Key Executive Appointments - TradingView
Lexeo appoints Jose Manuel Otero as COO - TipRanks
Lexeo Therapeutics announces key leadership appointments By Investing.com - Investing.com Nigeria
Lexeo Therapeutics announces key leadership appointments - Investing.com
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics - The Manila Times
Lexeo Therapeutics Announces Key Leadership Appointments to Drive Advances in Cardiovascular Medicine - Quiver Quantitative
New cardiology leaders join Lexeo as it backs novel cardiac RNA startup - stocktitan.net
Investor Mood: Can Lexeo Therapeutics Inc be the next market leaderJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Financial Analysis: Esperion Therapeutics (NASDAQ:ESPR) & Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Weekly Trades: Whats next for Lexeo Therapeutics Inc stockJuly 2025 Setups & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Volume Recap: Is Bassett Furniture Industries Incorporated stock technically oversoldWeekly Trade Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Fund Flows: What is GNSRTs debt to equity ratioWeekly Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
Market Wrap: Can Lexeo Therapeutics Inc ride the EV waveJuly 2025 Setups & Daily Technical Forecast Reports - baoquankhu1.vn
Technical Analysis: Is Lexeo Therapeutics Inc subject to activist investor interestJuly 2025 Macro Moves & Safe Entry Trade Reports - baoquankhu1.vn
Block Trades: Does Lexeo Therapeutics Inc have a sustainable dividend2025 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn
Does Lexeo Therapeutics Inc have a sustainable dividendPortfolio Value Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - MSN
Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright - TipRanks
Aug Update: Is SLAB subject to activist investor interestWeekly Investment Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aug Decliners: Will Lexeo Therapeutics Inc outperform its industry peersEarnings Risk Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Price Action: Will Lexeo Therapeutics Inc outperform its industry peersAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
LXEO: Cardiac gene therapy programs show strong efficacy, safety, and commercial readiness - TradingView — Track All Markets
Heart-disease gene therapy race heating up as Lexeo posts data - BioWorld MedTech
Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 6.5%Should You Sell? - MarketBeat
Day Trade: Will Lexeo Therapeutics Inc stock outperform growth indexesJuly 2025 Setups & Safe Entry Point Alerts - Bộ Nội Vụ
H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns - Investing.com Canada
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Aug Intraday: Will Lexeo Therapeutics Inc. stock deliver shareholder valueJuly 2025 Price Swings & Stepwise Trade Signal Guides - Bộ Nội Vụ
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat
Lexeo’s gene therapy shows promising results for heart condition By Investing.com - Investing.com Nigeria
Lexeo Therapeutics Reflects Structural Trends In Clinical Biotech - Kalkine Media
Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap DownHere's What Happened - MarketBeat
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results - TipRanks
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 - TradingView — Track All Markets
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):